Regeneration Therapy

Regeneration Therapy

Immunotherapy with thymus peptides

History
1560 Andreas Vesal gives the first trustworthy description of the thymus. 1913 Lamper circulates a research on the thymus gland function and reports on the results of a thymus therapy. 1922 Knipping treats patients with veal thymus pressed juice and observes and describes an increase in lymphocytes in the blood. 1936 Hammar formulates the hypothesis that there is a connection between the function of the thymus gland and the immunological processes that develop in the body after birth.
1961 A.P. Miller describes the role of the thymus gland as the control organ of the immune system. Since 1961 it is also known that rats that have the thymus removed die after a few weeks of general weakness, weight loss and infections. As time passed, the research on thymus enzymes, proteins, peptides and steroids clarified the role of the thymus as the control centre especially during the development and differentiation of the precursor cells stemming from the bone marrow to become immune-competent T-lymphocytes.

1964 NEZELOF syndrome is described: a recessive lympho deficiency characterised by a thymus hypoplasia. Mostly serum immunoglobulins and NK activity are present. The DIGEORGE syndrome combines an embryonal thymus hypoplasia
with hypoparathyroidism. The T- cell compartment is defective.

Thymus preparations
The administration of thymus hormones can improve or reduce various deficiencies.
Thymus peptides can induce the differentiation of lymphocytes.
It is essential for the outcome of the therapy that in the frame of the somministration a balanced stimulation is archived. Only the immune homostasis
represents an optimal situation.
Nowadays protein fractions (highly molecular components, polypeptides, oligopeptides) and steroid fractions are isolated. Thymoject from Biosyn is used.

Thymus therapy

Thymus peptide fractions have various effects:
• Lymphopoiesis improvement
The granulocytic phase is not substantially influenced, nor are NK cells.
• Stimulation
components that are still present or parts of the thymus tissue.
• Organisation of a homeostasis in the entire lymphocyte sub population.

Thymus therapy – Practical
• Long term: 1 Thymoject a week
• Stoss therapy

For fast stimulation of lymphopoiesis in case of acute cellular deficiency
• acute T-cell deficiency
After radiation, chemotherapy, surgery, in case of negative general condition.
• As a “small” short term stimulus in case of worsening immune condition.

1.Cycle:
Mo to Fri 1 Amp. per day Thymoject i.m.

Saturday/Sunday pause

2.Cycle:
Mo to Fri 1 Amp. per day Thymoject i.m.

In 14 days 10 Thymus peptide fractions are given.
It is possible to measure the effect only after 14 days. The comparison between blood samples should be carried out only after this time lapse. Earlier exams will show values that are too low, as the lymphocyte development phase will still be talking place.
Composition:
1 ml pyrogenfree injection – Lsg. contents : 50 mg thymus extract (extra glanulae thymi sicc. Vitul.; biotech., chromatographically standardised polypeptides with a molecular weight of <10000 Dalton.) Other components: water for injection purposes.

Use

Diseases that are connected to an immune defect, like tumors, rheumatic illnesses, allergic illnesses, endocrine regulation problems, geriatric conditions.
Counter indications
Hyper sensibility to polypeptides. In patients with allergic predisposition the tolerance to THYMOJECT® should be tested through an application of 0,1-0,5 ml (within 5-24 hours of the application no redness should appear).

Dose
Starting dose: 0,5-1,5 mg/kg daily, i.m., s.c., i.c., i.v. (only after test) for a duration of two weeks. Continuation dose: 0,5-1,5 mg/kg i.m, s.c., i.c., i.v. (only after test) 2-3 times/week;
THYMOJECT® can also be inhaled (1 ml 1-2 times/week). These method is also indicated with hyper sensitive patients. (1 ml 3-4 times/week).

Print Friendly, PDF & Email
Share